Is RECURSION PHARMACEUTICALS, INC. (RXRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.9% / 30% | 32.5% / 30% | 2.7% / 30% | 26.94% / 5% | ✗ NOT HALAL |
| DJIM | 5.9% / 33% | 32.5% / 33% | 2.7% / 33% | 26.94% / 5% | ✗ NOT HALAL |
| MSCI | 7.5% / 33% | 41.0% / 33% | 3.4% / 33% | 26.94% / 5% | ✗ NOT HALAL |
| S&P | 5.9% / 33% | 32.5% / 33% | 2.7% / 33% | 26.94% / 5% | ✗ NOT HALAL |
| FTSE | 7.5% / 33% | 41.0% / 33% | 3.4% / 50% | 26.94% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -328.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -59.5% | |
| Return on Assets (ROA) | -27.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$372M |
| Free Cash Flow | -$380M |
| Total Debt | $78M |
| Debt-to-Equity | 6.9 |
| Current Ratio | 5.5 |
| Total Assets | $1.5B |
Price & Trading
| Last Close | $3.15 |
| 50-Day MA | $3.76 |
| 200-Day MA | $4.75 |
| Avg Volume | 19.3M |
| Beta | 1.0 |
|
52-Week Range
$2.91
| |
About RECURSION PHARMACEUTICALS, INC. (RXRX)
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is RECURSION PHARMACEUTICALS, INC. (RXRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), RECURSION PHARMACEUTICALS, INC. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is RECURSION PHARMACEUTICALS, INC.'s debt ratio?
RECURSION PHARMACEUTICALS, INC.'s debt ratio is 5.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.5%.
What are RECURSION PHARMACEUTICALS, INC.'s key financial metrics?
RECURSION PHARMACEUTICALS, INC. has a market capitalization of $1.6B, and revenue of $74M. Return on equity stands at -59.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.